Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 30 September 2025 - 17 October 2025

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Hims & Hers Health launched a menopause and perimenopause care program on its Hers platform Oct. 15, triggering a one-day stock surge of up to 16%. Shares quickly reversed, falling 11% to around $52–53 by Oct. 17. The company aims for $1 billion annual revenue in women’s health by 2026. Analysts remain divided, citing high valuation and volatile trading despite rapid revenue growth.
17 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly shares hit a record $832 intraday on Oct. 1, fueled by demand for its obesity drugs and Alzheimer’s advances, before slipping 4% after Donald Trump pledged to cut weight-loss drug prices. Lilly’s Mounjaro and ZepBound now hold 57% of U.S. GLP-1 prescriptions, outpacing Novo Nordisk. First-half 2025 revenue jumped about 40% year-on-year. Most analysts remain bullish, despite valuation and policy concerns.
17 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Novo Nordisk shares fell 6.7% in Copenhagen on Oct. 17, 2025, and U.S. pre-market quotes pointed to a further 4.8% drop. The stock has lost over 40% year-to-date, erasing hundreds of billions in value. Recent acquisitions and job cuts have not reversed investor caution, as competition from Eli Lilly intensifies and analysts warn of more profit downgrades.
17 October 2025
··
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares jumped 180% to $162 on Oct. 16 after its lead drug, ulixacaltamide, met all key endpoints in two Phase 3 trials for essential tremor. The rally added nearly $3 billion to the company’s market cap. Praxis announced a $525 million public offering to fund commercialization and pipeline expansion. Analyst price targets surged, with several now above $250.
17 October 2025
··
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX shares jumped over 30% in early trading Oct. 16 after Scienture announced Arbli, the first FDA-approved ready-to-use liquid losartan, is now available through major wholesalers. The stock hit an intraday high of $1.12 before trading near $0.71 by mid-day. Scienture recently secured a major rebate deal to drive Arbli’s adoption. Analysts remain cautious, citing weak financials and high volatility.
16 October 2025
··
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune Therapeutics shares surged 42% on October 8, 2025, after nearly doubling intraday on September 19, despite no major news and record trading volumes. The company sold its key T-cell therapy programs, including Tecelra, to US WorldMeds for $55 million upfront to pay off debt and avoid insolvency. Q2 net loss reached $30.3 million, with cash reserves at $26 million by mid-year. Analysts remain bearish, with no major buy ratings.
16 October 2025
··
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Hims & Hers shares jumped 16% on Oct. 15 after launching a menopause care program, trading near $62.80 on Oct. 16, up 7% for the day. The stock has more than doubled in 2025, far outpacing rivals like Teladoc. Regulatory scrutiny from the FDA and FTC triggered brief sell-offs in September. Analyst sentiment remains cautious, with most price targets in the high $30s despite recent gains.
16 October 2025
··
AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca shares traded near £127.82 ($85 ADR) on Oct. 10, 2025, close to a 52-week high after a U.S. NYSE listing and a $4.5 billion Virginia plant announcement. Market cap stands at $264 billion, with 2024 revenue of $54.1 billion, up 18%. The company agreed to provide U.S. Medicaid with its lowest global drug prices. Shares have rallied over 10% since late September.
11 October 2025
···
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics shares surged over 30% to nearly $89 on October 10, 2025, after reports that Johnson & Johnson is in talks to acquire the company. Trading was briefly halted due to volatility. The company, valued at about $5.4 billion, recently announced positive trial results for its lead drugs and secured major partnerships with J&J and Takeda.
11 October 2025
·····
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, paying $54 per share in cash plus a potential $6 per share if Akero’s lead drug wins U.S. approval by 2031. Akero’s efruxifermin, in Phase 3 trials for fatty liver disease, has shown reversal of liver fibrosis in mid-stage studies. Akero shares jumped 19% on the news, while Novo shares were little changed. The deal is expected to close by year-end.
9 October 2025
··
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

Acurx Pharmaceuticals shares have fallen about 90% from their 52-week high, trading near $4.30 after a 1-for-20 reverse split in August. The stock briefly rallied in late September after the European Medicines Agency issued a positive opinion on its pediatric plan for ibezapolstat. Acurx remains pre-revenue with $6.1 million in cash at Q2’s end and faces additional funding needs for Phase 3 trials.
8 October 2025
·
Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

Manufacturing accounts for up to 47% of Puerto Rico’s GDP and delivered over $50 billion in output in 2020, supporting more than 220,000 jobs. Amgen is investing $926.7 million in Juncos, creating nearly 3,000 jobs. At least seven manufacturers have announced expansions since 2020, with $220 million in new commitments. The island faces competition, power outages, and workforce shortages.
6 October 2025
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

Cidara Therapeutics’ stock rose 279% year-to-date, closing at $101.99 on Oct. 3, 2025, up from $26.88 at the start of the year. The company’s CD388 drug showed 76% protection against flu in a Phase 2b trial. BARDA awarded up to $339 million in October for manufacturing and clinical development. As of June, Cidara held $516.9 million in cash.
4 October 2025
··
Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus (NASDAQ:TARS) surged 10.9% to $65.17 on Oct. 3, 2025, after reporting Q2 net product revenue of $102.7 million, up 152% year-over-year, driven by XDEMVY eyedrop sales. Shares have climbed 31% in the past month and 84% over the year. Wall Street consensus rates the stock a “Buy,” with average 12-month targets near $71. Losses are narrowing as sales rise and cash reserves remain strong.
3 October 2025
···
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

SRPT closed at $19.57 on Oct 2, up 6.8% for the day and nearly 16% over the past month, but remains down about 82% year-to-date. The company restructured in July, cutting 500 jobs and pausing some gene therapy trials after FDA safety concerns. Sarepta resumed shipments of Elevidys for ambulatory DMD patients following FDA guidance. Analyst consensus is “Hold,” with price targets ranging from $14 to $39.
2 October 2025
··
Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

President Trump will announce “TrumpRx,” a federal website allowing Americans to buy discounted prescription drugs directly. The White House secured a deal with Pfizer to cut U.S. prices on several medications and invest $70 billion in domestic research. Drugmakers responded with new direct-sales programs and pledged $500 billion in U.S. investments. Some experts warn price controls could limit innovation and shift higher costs overseas.
30 September 2025
·
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Pfizer shares closed near a 52-week low at $24.40 on Sept. 30, 2025, despite Q2 revenue of $14.7 billion and adjusted EPS of $0.78, both above expectations. The company raised full-year EPS guidance and announced a $4.9 billion deal to acquire obesity drugmaker Metsera. President Trump unveiled a pact for Pfizer to cut U.S. drug prices and sell through a new TrumpRx site. FDA approved Pfizer’s updated COVID-19 vaccine for high-risk groups.
30 September 2025
··
1 … 35 36 37 38

Stock Market Today

  • Top 5 Singapore Next 50 Stocks Outperform Blue Chips in Q1 2026
    April 11, 2026, 12:17 AM EDT. In Q1 2026, amid market volatility spurred by geopolitical tensions and rising oil prices, five Singapore Next 50 stocks outpaced blue chips with substantial gains. Frencken Group led with a 47.8% total return, driven by confidence in semiconductor recovery and expected capacity expansions in the US, Singapore, and Malaysia. The company reported better-than-expected FY2025 margins and growth in semiconductor and industrial automation divisions, despite a revenue dip in analytical life sciences. These outperformers highlight resilient pockets within Singapore equities, offering investors diversification beyond traditional blue chips during a turbulent first quarter.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 12:19 AM EDT Top 5 Singapore Next 50 Stocks Outperform Blue Chips in Q1 2026 April 11, 2026, 12:17 AM EDT. In Q1 2026, amid market volatility spurred by geopolitical tensions and rising oil prices, five Singapore Next 50 stocks outpaced blue chips with substantial gains. Frencken Group led with a 47.8% total return, driven by confidence in semiconductor recovery and expected capacity expansions in the US, Singapore, and Malaysia. The company reported better-than-expected FY2025 margins and growth in semiconductor and industrial automation divisions, despite a revenue dip
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop